Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Tuulia Vallius, Ph.D., M.D.

Profile Picture

University of Turku, Turku, FinlandMD12/2012medicine
University of Turku, Turku, FinlandPhD02/2018ovarian cancer neoadjuvant chemotherapy treatment response evaluation

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Yapp C, Novikov E, Jang WD, Vallius T, Chen YA, Cicconet M, Maliga Z, Jacobson CA, Wei D, Santagata S, Pfister H, Sorger PK. UnMICST: Deep learning with real augmentation for robust segmentation of highly multiplexed images of human tissues. Commun Biol. 2022 11 18; 5(1):1263. PMID: 36400937; PMCID: PMC9674686.
    Citations:    Translation:HumansAnimalsCells
  2. Nirmal AJ, Maliga Z, Vallius T, Quattrochi B, Chen AA, Jacobson CA, Pelletier RJ, Yapp C, Arias-Camison R, Chen YA, Lian CG, Murphy GF, Santagata S, Sorger PK. The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution. Cancer Discov. 2022 06 02; 12(6):1518-1541. PMID: 35404441; PMCID: PMC9167783.
    Citations: 4     Fields:    Translation:Humans
  3. Goldberg J, Pastorello RG, Vallius T, Davis J, Cui YX, Agudo J, Waks AG, Keenan T, McAllister SS, Tolaney SM, Mittendorf EA, Guerriero JL. The Immunology of Hormone Receptor Positive Breast Cancer. Front Immunol. 2021; 12:674192. PMID: 34135901.
    Citations: 9     Fields:    Translation:HumansCells
  4. Keenan TE, Li T, Vallius T, Guerriero JL, Tayob N, Kochupurakkal B, Davis J, Pastorello R, Tahara RK, Anderson L, Conway J, He MX, Shannon E, Godin RE, Sorger PK, D'Andrea A, Overmoyer B, Winer EP, Mittendorf EA, Van Allen EM, Shapiro GI, Tolaney SM. Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2021 02 15; 27(4):983-991. PMID: 33257427; PMCID: PMC7887044.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  5. Kozlowska E, Vallius T, Hynninen J, Hietanen S, Färkkilä A, Hautaniemi S. Author Correction: Virtual clinical trials identify effective combination therapies in ovarian cancer. Sci Rep. 2020 Jul 22; 10(1):12531. PMID: 32694595; PMCID: PMC7374732.
    Citations:    Fields:    
  6. Kozlowska E, Vallius T, Hynninen J, Hietanen S, Färkkilä A, Hautaniemi S. Virtual clinical trials identify effective combination therapies in ovarian cancer. Sci Rep. 2019 12 10; 9(1):18678. PMID: 31822719.
    Citations: 3     Fields:    Translation:Humans
  7. Kozlowska E, Färkkilä A, Vallius T, Carpén O, Kemppainen J, Grénman S, Lehtonen R, Hynninen J, Hietanen S, Hautaniemi S. Mathematical Modeling Predicts Response to Chemotherapy and Drug Combinations in Ovarian Cancer. Cancer Res. 2018 07 15; 78(14):4036-4044. PMID: 29769198.
    Citations: 9     Fields:    Translation:Humans
  8. Vallius T, Hynninen J, Kemppainen J, Alves V, Auranen K, Matomäki J, Oksa S, Virtanen J, Grénman S, Auranen A, Seppänen M. 18F-FDG-PET/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer. Eur J Nucl Med Mol Imaging. 2018 07; 45(7):1224-1232. PMID: 29476227.
    Citations: 13     Fields:    Translation:Humans
  9. Vallius T, Hynninen J, Auranen A, Matomäki J, Oksa S, Roering P, Grènman S. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer. Tumour Biol. 2017 Feb; 39(2):1010428317691189. PMID: 28218038.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  10. Vallius T, Peter A, Auranen A, Carpén O, Kemppainen J, Matomäki J, Oksa S, Roering P, Seppänen M, Grénman S, Hynninen J. 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer. Gynecol Oncol. 2016 Jan; 140(1):29-35. PMID: 26515076.
    Citations: 14     Fields:    Translation:Humans
  11. Vallius T, Hynninen J, Auranen A, Carpén O, Matomäki J, Oksa S, Virtanen J, Grénman S. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer. Tumour Biol. 2014 Dec; 35(12):12389-95. PMID: 25190018.
    Citations: 18     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Vallius's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (63)
Co-Authors (20)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.